Clinical Takeaway
GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were examined using Mendelian randomization to determine whether they causally affect the risk of ten common mental health conditions, including depression, anxiety, PTSD, and substance use disorders. This genetic analysis approach helps reduce confounding that limits traditional observational studies. The findings add to a growing body of evidence evaluating whether these widely prescribed metabolic medications carry meaningful psychiatric risks or benefits beyond their primary indications.
#27 Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.
Citation: Xiang Longgang et al.. Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.. International journal of molecular sciences. 2025. PMID: 40141382.
Design: 6 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: -2
This Mendelian randomization study provides genetic evidence for potential causal effects of GLP1R agonists on mental illness risk, which is clinically significant given the widespread prescription of these agents for diabetes and obesity management. If validated, these findings could inform psychiatric risk assessment in patients initiating GLP1RA therapy and identify GLP1R signaling as a mechanistic target for psychiatric intervention. The establishment of causal rather than merely associative relationships strengthens the rationale for prospective clinical trials examining GLP1RA safety and efficacy in primary psychiatric populations.
Quality Gate Alerts:
- Preclinical only
Abstract: Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists may have potential benefits for mental illnesses. However, their exact effects remain unclear. This study investigated the causal relationship between glucagon-like peptide-1 receptor agonist (GLP1RA) and the risk of 10 common mental illnesses, including attention deficit and hyperactivity disorder, anorexia nervosa, anxiety disorder, autism spectrum disorder, bipolar disorder, major depressive disorder, post-traumatic stress disorder, schizophrenia, cannabis use disorder, and alcohol use disorder. We selected GLP1RA as the exposure and conducted a Mendelian randomization (MR) analysis. The cis-eQTLs of the drug target gene GLP1R, provided by eQTLGen, were used to simulate the pharmacological effects of GLP1RA. Type 2 diabetes and BMI were included as positive controls. Using data from both the Psychiatric Genomic Consortium and FinnGen, we conducted separate MR analyses for the same disease across these two independent databases. Meta-analysis was used to pool the results. We found genetic evidence suggesting a causal relationship between GLP1RA and a reduced risk of schizophrenia [OR (95% CI) = 0.84 (0.71-0.98), I2 = 0.0%, common effects model]. Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI. However, the findings of this study provide insufficient evidence to support a causal relationship between GLP1RA and other mental illnesses. Sensitivity analyses did not reveal any potential bias due to horizontal pleiotropy or heterogeneity in the above results (p > 0.05). This study suggests that genetically proxied activation of glucagon-like peptide-1 receptor is associated with a lower risk of schizophrenia. GLP1R is implicated in schizophrenia pathogenesis, and its agonists may exert potential benefits through weight management. Our study provides useful information for understanding the neuropsychiat
🧠 This Mendelian randomization study suggesting potential causal links between GLP1R agonists and reduced risk of common mental illnesses is intriguing from a mechanistic standpoint, but several important caveats warrant careful interpretation in clinical practice. The study relies on genetic variants as instrumental variables rather than direct clinical observation, which means the findings represent theoretical associations rather than proven therapeutic effects, and the generalizability to real-world cannabis patients remains entirely unclear. Additionally, many patients using cannabis medicine may also have metabolic comorbidities or be considering GLP1R agonists for weight management, creating complex confounding scenarios that this genetic approach cannot fully disentangle. Until prospective clinical trials directly examine GLP1R agonists as adjunctive or primary treatments for the mental health conditions studied, practitioners should view these results as hypothesis-generating rather than actionable evidence, and continue individualized assessment of cannabis use in the context of each patient’s complete medication regimen and mental health trajectory.